Oncode Scientific

Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Menu
Slide
Revolutionizing the Cancer Battle
ELEVATING QUALITY OF LIFE AMIDST THE FIGHT

At Oncode, we are dedicated to guiding you towards the best possible decisions in your cancer treatment journey. With our personalized precision medicine tests, we provide you with the confidence and assurance that you are always on the right track. By tailoring our approach to your unique genetic profile, we empower you to make informed choices and embrace precision medicine for optimal treatment outcomes.

Slide
A New Way In Battling Cancer
COMPROMISE NOT ON YOUR QUALITY OF LIFE WHILE YOU BATTLE AGAINST CANCER

In Oncode, we want to help you in making the right choice and the best possible decisions when it comes to cancer treatments. Oncode tailormade precision medicine tests enable you to be rest assured that you are always on the right track.

Slide
A New Way In Battling Cancer
COMPROMISE NOT ON YOUR QUALITY OF LIFE WHILE YOU BATTLE AGAINST CANCER

In Oncode, we want to help you in making the right choice and the best possible decisions when it comes to cancer treatments. Oncode tailormade precision medicine tests enable you to be rest assured that you are always on the right track.

Slide
Revolutionizing the Cancer Battle
ELEVATING QUALITY OF LIFE AMIDST THE FIGHT

At Oncode, we are dedicated to guiding you towards the best possible decisions in your cancer treatment journey. With our personalized precision medicine tests, we provide you with the confidence and assurance that you are always on the right track. By tailoring our approach to your unique genetic profile, we empower you to make informed choices and embrace precision medicine for optimal treatment outcomes.

Slide
A New Way In Battling Cancer
COMPROMISE NOT ON YOUR QUALITY OF LIFE WHILE YOU BATTLE AGAINST CANCER

In Oncode, we want to help you in making the right choice and the best possible decisions when it comes to cancer treatments. Oncode tailormade precision medicine tests enable you to be rest assured that you are always on the right track.

Slide
A New Way In Battling Cancer
COMPROMISE NOT ON YOUR QUALITY OF LIFE WHILE YOU BATTLE AGAINST CANCER

In Oncode, we want to help you in making the right choice and the best possible decisions when it comes to cancer treatments. Oncode tailormade precision medicine tests enable you to be rest assured that you are always on the right track.

How We Help in Your Cancer Treatment?

Identify the Genetic Alterations of your Cancer
Knowing the root genetic alterations that cause the occurrence of your cancer enable us to provide your physician with treatment options tailor-made to battle against your cancer
Your Personalize Report with Beneficial Drugs Suggestion
Oncode report suggests list of treatment options including targeted therapy, immunotherapy, chemotherapy, radiation, hormonal therapy & more, which work optimally for you
Ruling-Out & Avoid Less Beneficial Treatments
Based on your genetic profile, Oncode report gives you information on treatment options which are less effective/ beneficial to you; so that your physician may avoid using them
Aid to Plan for the most Cost-Effective Treatment Approach
By choosing the most suitable treatment option(s), you can avoid trial & error approaches which will simply lessen your financial burden, and minimizing unnecessary side effects
Listing of Available Free Drug Clinical Trials
Oncode report connects patients with matching eligibility to clinical trials held by distinguished pharmaceutical companies. Enrolment provides access to free new drugs
Precision Medicine Tests are Covered by Insurance
Depending on your insurance policy, most insurance companies do cover the cost of genetic profiling. You may contact us to obtain the insurance claim form to be submitted to your insurance company for claim
Identify the Genetic Alterations of your Cancer
Knowing the root genetic alterations that cause the occurrence of your cancer enable us to provide your physician with treatment options tailor-made to battle against your cancer
Your Personalize Report with Beneficial Drugs Suggestion
Oncode report suggests list of treatment options including targeted therapy, immunotherapy, chemotherapy, radiation, hormonal therapy & more, which work optimally for you
Ruling-Out & Avoid Less Beneficial Treatments
Based on your genetic profile, Oncode report gives you information on treatment options which are less effective/ beneficial to you; so that your physician may avoid using them
Aid to Plan for the most Cost-Effective Treatment Approach
By choosing the most suitable treatment option(s), you can avoid trial & error approaches which will simply lessen your financial burden, and minimizing unnecessary side effects
Listing of Available Free Drug Clinical Trials
Oncode report connects patients with matching eligibility to clinical trials held by distinguished pharmaceutical companies. Enrolment provides access to free new drugs
Precision Medicine Tests are Covered by Insurance
Depending on your insurance policy, most insurance companies do cover the cost of genetic profiling. You may contact us to obtain the insurance claim form to be submitted to your insurance company for claim

If you are diagnosed with

Solid Tumours
Blood Cancers

We Offer

TISSUE BIOPSY

At Oncode, we offer a comprehensive range of tests utilizing the patient’s tissue biopsy. Explore our extensive list of tissue biopsy tests available today!

LIQUID BIOPSY (BLOOD)

Discover our cutting-edge liquid biopsy test, which allows for non-invasive tumor profiling using only a patient’s blood sample. Explore the benefits of our liquid biopsy test today!

REAL-LIFE ONCODE PATIENT CASE STUDIES

48 Years Old Female, Anaplastic/Poorly Differentiated Thyroid Carcinoma
This case study describes a 48-year-old female patient diagnosed with anaplastic/poorly differentiated thyroid carcinoma in 2018, accompanied by minor lung and brain metastases. The initial treatment plan involved chemotherapy, with a projected life expectancy of two months without it. Seeking a second opinion, the patient underwent next-generation sequencing (NGS) testing at Oncode, which revealed an ALK gene fusion alteration—a biomarker indicating the potential effectiveness of ALK inhibitors.

Considering the rarity of ALK fusion in anaplastic thyroid carcinoma, Oncode team suggested the possibility of the cancer originating from the lungs. Nonetheless, identification of ALK fusion in a non-NSCLC tumor could offer benefits from ALK inhibitors. This new insight influenced the diagnosis. Following targeted drug treatment, the patient experienced significant health improvement and continues to surpass initial expectations in terms of survival.

This case study highlights the power of precision medicine in uncovering the complex nature of cancer and providing more accurate treatment options. By leveraging genomic testing and targeted therapies, the patient’s prognosis drastically changed from a projected two-month life expectancy to over six years (last interview with patient was at early 2023), exemplifying the potential of genetic testing and targeted therapies to transform patients’ outcomes.

REAL-LIFE ONCODE PATIENT CASE STUDIES

54 Years Old Female, NSCLC, Exon 19 deletion
In October 2021, a PCR test revealed the patient’s EGFR positivity but absence of the BRAF mutation, indicating the potential efficacy of EGFR inhibitors (EGFR TKI). Surprisingly, the patient failed to respond to both EGFR TKI and second-line chemotherapy.

In January 2023, Oncode conducted a liquid biopsy NGS test on the patient’s sample, which showed a positive result for both EGFR and BRAF mutations. The presence of the BRAF gene mutation is known to render EGFR targeted therapy ineffective.

There are two possible explanations for the initial negative BRAF result. Firstly, the initial negative BRAF result could be the emergence of a new mutation, however, the mutation may have been present from the beginning and contributed to the lack of response to the treatment. Secondly, it is believable that the limited sensitivity of the PCR test (typically 95% compared to NGS’s 99.9% LOD) may have resulted in the earlier detection failure of low allele frequency BRAF mutations.

This case highlights the critical importance of testing sensitivity to avoid missed diagnoses or misdiagnoses, thereby ensuring that patients receive appropriate and effective targeted therapies.

REAL-LIFE ONCODE PATIENT CASE STUDIES

37 Years Old, Female, Advanced Colorectal Cancer, Peritoneal Metastasis, Refractory
The patient underwent PCR testing, and the KRAS test result came back negative, indicating a potentially better response to anti-EGFR therapies. However, despite treatment with oxaliplatin, irinotecan, cetuximab, and bevacizumab, the patient did not show any improvement, and her condition continued to worsen.

In light of this, the doctor decided to pursue a liquid biopsy NGS test with Oncode. The test revealed a positive KRAS gene mutation with a mutant allele frequency of 0.7%, which is below the limit of detection (LOD) for most PCR and some NGS tests.

It is well-established that colorectal cancer with KRAS mutations should not be treated with cetuximab or panitumumab due to the activation of alternate signaling pathways and/or structural changes in the EGFR protein.

This case underscores the importance of sufficient sensitivity in detection methods. Insufficient sensitivity may lead to false-negative results, resulting in misdiagnosis or delayed treatment.

REAL-LIFE ONCODE PATIENT CASE STUDIES

56 Years Old Female, NSCLC with EGFR L858R
In 2019, the patient received a diagnosis of NSCLC with an EGFR L858R mutation and underwent first-line treatment with EGFR TKIs. In 2022, the doctor performed a liquid biopsy NGS with Oncode to monitor the patient’s treatment response. Despite a low allele frequency of only 0.1%, the liquid biopsy NGS successfully detected the presence of the EGFR T790M mutation. This finding is significant as the T790M mutation is known to be associated with acquired resistance to first-generation EGFR TKIs. Approximately 50% of patients initially respond to treatment but eventually develop resistance, often within 9-14 months. The early detection of the T790M mutation through a highly sensitive test offers valuable information to the doctor, enabling prompt modification of the treatment plan to achieve better outcomes.

REAL-LIFE ONCODE PATIENT CASE STUDIES

35 Years Old Male, NSCLC Primary, Failed Osimertinib
Multiple EGFR mutations, including T790M and C797S, were identified in a 35-year-old NSCLC patient who had failed third-line EGFR-TKI treatment, using the Oncode NGS test.

It is noteworthy that both the T790M and C797S variants were detected in the same allele in a cis configuration, indicating resistance to all EGFR-TKIs.

In T790M-positive NSCLCs that exhibit resistance to erlotinib and subsequently acquire a C797S mutation following third-generation TKI treatment, the configuration of these two mutations plays a crucial role in determining the response to therapy. If the mutations are in trans (on separate alleles), a combination of first- and third-generation TKIs may restore EGFR inhibition. However, if the mutations are in cis (on the same allele), the cancer cells become unresponsive to all EGFR TKIs, including the combination of first- and third-generation inhibitors.

It is important to note that the assessment of cis versus trans configurations can be determined by specific NGS approaches, although not all assays and bioinformatics pipelines can accurately distinguish between them. Nevertheless, identifying the cis or trans configuration of T790M and C797S mutations is crucial information that provides valuable insights into treatment indications for patients.

REAL-LIFE ONCODE PATIENT CASE STUDIES

52 Years Old Male, Acute Myeloid Leukemia
The patient underwent both PCR and NGS testing in different labs to determine the status of the FLT3-ITD gene. The PCR test indicated that FLT3-ITD was positive, while the NGS test showed it as negative. In order to obtain confirmation, sample was sent to Oncode for further analysis confirmation. Upon examination, both Oncode’s PCR and NGS tests confirmed that FLT3-ITD was indeed positive. It is worth noting that depending on the specific assay design used by individual laboratories, FLT3-ITD detection by NGS can sometimes be missed.

As FLT3-ITD is recognized as a challenging marker to detect accurately using NGS, it holds significant importance as a risk marker that directly impacts prognosis, treatment decisions, and overall clinical management in acute myeloid leukemia (AML). Therefore, it is crucial to thoroughly assess the performance of FLT3-ITD detection and accurately classify its allelic ratio to prevent missed diagnoses.

To ensure comprehensive examination and coverage of tests offered, Oncode conducts PCR and Fragment Analysis in parallel with NGS for all panels involving the FLT3 gene. This additional quality control step aims to provide a complete assessment of FLT3-ITD status and enhance the accuracy of the testing process.

HOW TO ORDER A TEST FROM ONCODE

ASSESSMENT

Clinicians will perform clinical examination, and contact Oncode technical support team for the selection of appropriate genetic tests.

ORDERING

Clinician will fill in the Test Requisition Form in Oncode specimen collection kit. Draw blood from patients and/or request hospital labs to prepare FFPE specimens (if required).

ANALYSIS

Oncode laboratory will perform tests, generate and send reports to clinicians within stated turn-around time.

RESULTS

Clinicians will explain report to patients. Clinical support team of Oncode laboratory is available for support and explanation of test results.

WISH TO KNOW MORE ABOUT ONCODE TEST?

Precision medicine, also known as personalized medicine, is an approach that takes into account individual variations in genes to tailor medical treatments and interventions. Before the advent of precision medicine, many patients with the same type and stage of cancer would often receive similar standard treatments. However, it was observed that these treatments could be more effective for some individuals while being less effective or even ineffective for others.

Through research and advancements in genetics, scientists and healthcare professionals have discovered that genetic variations play a crucial role in how diseases, including cancer, develop, progress, and respond to treatments. By analyzing a person’s genetic makeup, doctors can gain insights into the specific genetic alterations that contribute to the growth and spread of cancer cells, enabling them to select personalized treatment plans that are more likely to be effective.

This approach can improve treatment outcomes, minimize adverse effects, and optimize the overall effectiveness of cancer therapies.

Precision medicine plays a crucial role in cancer treatment planning by analyzing the genetic makeup of a patient’s tumor to develop a precise clinical understanding of the patient. Each patient’s cancer is unique, influenced by a complex interaction between genetic factors and the environment. Through genetic sequencing, specific genetic alterations or mutations that drive the cancer’s growth can be identified. 

By examining the genetic profile of the tumor, healthcare providers can select targeted therapies that directly address the identified genetic abnormalities. This personalized approach enhances treatment outcomes by utilizing treatments that are more likely to be effective and avoiding those that may not be suitable for the specific genetic profile. Precision medicine also aids in predicting how a patient will respond to treatment and helps identify clinical trials that offer innovative therapies.

Overall, the application of genetic sequencing and precision medicine enables tailored cancer treatments based on an individual patient’s genetic characteristics. This approach significantly improves the effectiveness and outcomes of cancer therapies, ultimately enhancing patient care and quality of life.

Oncode genetic profiling report examines mutations or alterations in cancer cells and provides comprehensive information and recommendations, including:
  • Beneficial targeted therapies: The report provides information on FDA-approved therapies that are effective against the specific mutations found in your cancer.
  • Less beneficial therapies: The report highlights therapies that may have limited effectiveness against the identified mutations in your cancer.
  • Clinical trial options: It suggests potential clinical trials for treatments that are currently in development and may be eligible based on the genetic profile of your cancer.
  • Hereditary implications: The report provides information whether the identified mutations could be inherited and passed down to your children.
  • Monitoring mutations: The report also includes information on the presence of new mutations that may arise during or after treatment, helping the doctor plan your treatment accordingly.
Even if the report shows no actionable mutations, this information remains valuable for your doctor to consider when planning your treatment.

Targeted cancer therapies are treatments that specifically target the molecular and genetic abnormalities found in cancer cells. Unlike traditional chemotherapy, which can affect both healthy and cancerous cells, targeted therapies are designed to selectively inhibit or disrupt the specific molecules or pathways that contribute to cancer growth and progression. These therapies work by interfering with specific molecules involved in cancer cell signaling, growth, or survival.

Yes, you can undergo genetic testing even if you have already received chemotherapy treatment. The timing and suitability of genetic testing may depend on various factors, including the stage of your cancer, the specific type of test and your individual medical history. It is recommended to consult with your healthcare provider to determine the most appropriate timing for genetic testing in relation to your chemotherapy treatment. They will consider your specific circumstances and provide guidance on the feasibility and potential benefits of genetic testing in your case.

Genetic counseling is available if required to support patients throughout their genetic testing journey. Pre-test genetic counseling sessions aim to provide education about genetics, including an explanation of risk factors and the benefits of undergoing genetic testing. This session equips patients and their family members with the knowledge needed to make informed decisions regarding genetic testing.
Following the completion of genetic testing, post-testing genetic counseling sessions are conducted to help patients and their families understand the test results and their potential implications for future health. During these sessions, patients can explore strategies for managing their condition and discuss the risk of recurrence of the condition  in other family members.

The likelihood of a successful insurance claim depends on the specific policies of individual insurance companies. However, we have had positive experiences with major insurance companies, with success rates for claims exceeding 90%.

It is crucial to understand that insurance policies can differ between companies and countries. To ensure coverage, we recommend contacting your local insurance company directly to inquire about the specifics of your policy.